TSX gains after CPI shows US inflation rose 3%
Investing.com - BTIG raised its price target on Intuitive Surgical (NASDAQ:ISRG), the $166 billion medical technology leader, to $589.00 from $529.00 on Wednesday, while maintaining a Buy rating following the company’s third-quarter 2025 results. The company, which maintains a robust gross margin of 67%, has demonstrated strong revenue growth of 21% over the last twelve months.
The medical device maker reported revenue of $2.505 billion, representing 22.9% year-over-year growth, and adjusted earnings per share of $2.40. These results exceeded BTIG’s estimates of $2.362 billion in revenue and $1.85 in adjusted EPS. According to InvestingPro, the company maintains an excellent Financial Health score of 3.26 out of 5, with particularly strong marks in profitability and growth metrics.
Procedure growth for Intuitive’s da Vinci surgical systems outpaced market expectations by approximately 300 basis points, while system placements beat projections by seven units. The company also raised its procedure growth guidance by about 100 basis points for the fourth quarter of 2025. With a current ratio of 5.17, Intuitive Surgical maintains strong liquidity to support its growth initiatives. Get deeper insights into ISRG’s growth potential with a comprehensive Pro Research Report, available exclusively on InvestingPro.
BTIG noted that while a day-rate dynamic boosted procedures outside the United States by approximately 100 basis points in the third quarter (about 30 basis points worldwide), the overall performance remained impressive.
The research firm believes Intuitive Surgical has significant runway in its trade-in cycle, with healthy procedure demand driving higher projections for what BTIG considers a key bellwether in the medical technology sector.
In other recent news, Intuitive Surgical reported strong third-quarter results, with sales and earnings per share surpassing expectations by 4% and 20%, respectively, as noted by RBC Capital. Following this performance, RBC Capital raised its price target for Intuitive Surgical to $625 while maintaining an Outperform rating. Similarly, Evercore ISI increased its price target for the company to $540, citing strong overall performance and increased system placements, procedures, and utilization. Bernstein SocGen Group also reiterated an Outperform rating with a price target of $685, highlighting the positive potential in the company’s third-quarter results, particularly in system placements and procedure volumes.
In additional developments, Intuitive Surgical received clearance from the U.S. Food and Drug Administration for AI enhancements to its Ion lung biopsy system. These advancements introduce artificial intelligence into the navigational workflow and integrate advanced imaging capabilities, improving the robotic-assisted bronchoscopy platform. These recent developments reflect the company’s ongoing efforts to enhance its product offerings and maintain strong market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.